Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity
Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties
BOSTON, Aug. 14, 2025 /PRNewswire/ -- Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), today announced a collaboration with Eli Lilly and Company ("Lilly") to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. The collaboration will leverage Superluminal's cutting-edge, structure-based drug discovery platform, combined with Lilly's small molecule development and commercialization expertise, to rapidly advance potentially life-changing therapeutics.
"Our collaboration with Lilly is a defining moment for Superluminal, and a testament to the power of our platform to deliver high-quality development candidates against historically intractable GPCR targets," said Cony D'Cruz, CEO of Superluminal. "Together, we aim to develop next-generation medicines that address the urgent and growing global burden of cardiometabolic disease. We are very excited to be embarking on this collaboration just as we begin to advance our internal drug candidate targeting rare genetic forms of obesity and hypothalamic obesity, and we are committed to bringing safe, efficacious, novel treatments to patients affected by these challenging conditions."
Under the terms of the agreement with Lilly, Superluminal will apply its proprietary platform to discover and optimize small-molecule therapeutics for undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. Lilly will receive exclusive rights to develop and commercialize compounds arising from the collaboration after Superluminal delivers development candidates that meet predefined criteria. Superluminal is eligible to receive up to $1.3 billion, which includes upfront and near-term payments, an equity investment, development and commercial milestones, as well as tiered royalties on net sales.
Superluminal's platform integrates deep structural biology, machine learning, and proprietary pharmacokinetic and toxicology prediction tools to accelerate the discovery of candidate-ready small molecules. Initial efforts have focused on GPCRs, a historically challenging target class, where functional selectivity and structural complexity demand next-generation computational solutions.
Superluminal is headquartered in Lilly Gateway Labs, Boston, and is backed by a strong network of investors, including RA Capital Management, Insight Partners, NVentures (NVIDIA's venture capital arm), Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley.
About Superluminal MedicinesSuperluminal's platform has achieved a deep integration of AI/ML with biology, structural biology, and chemistry expertise to build the foundation for next-gen R&D and accelerate the discovery of candidate-ready compounds. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. The company's proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets, including its wholly owned lead program, a best-in-class, selective, and biased MC4R agonist for the treatment of obesity, which is expected to enter the clinic in 2026.
For more, visit www.superluminalrx.com.
Superluminal Media ContactSarah SuttonEndurance PRsarah@endurancepr.com(518) 932-3680
View original content to download multimedia:https://www.prnewswire.com/news-releases/superluminal-medicines-announces-collaboration-with-eli-lilly-and-company-to-advance-small-molecule-therapeutics-for-cardiometabolic-diseases-and-obesity-302529689.html
SOURCE Superluminal Medicines
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...
Net Loss: $33.5 million or $0.58 per share for Q1 2025, compared to $31.4 million or $0.54 per share in Q4 2024. Cash and Investments: $52.5 million as of March 31, 2025. Debt Reduction: Total debt reduced by $10 million, with near-term repayment obligations lowered from $118 million to $17 million. OMIDRIA Royalties: $6.7 million for Q1 2025 based on net sales of $22.3 million, down from $10.1 million in Q4 2024. Interest Expense: $3.7 million for Q1 2025, reflecting a $477,000 increase from Q4 2024. Operating Expenses: $35 million for Q1 2025, a decrease of $691,000 from Q4 2024. Income from Discontinued Operations: $4.1 million for Q1 2025, down $1.1 million from Q4 2024. Warning! GuruFocus has detected 2 Warning Signs with OMER. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Omeros Corp (NASDAQ:OMER) has successfully negotiated an exchange agreement to extend the maturity of its convertible notes from 2026 to 2029, reducing near-term debt obligations by over $100 million. The company has an active at-the-market facility with the capacity to raise up to $150 million, providing flexibility to access additional capital. The FDA has accepted the resubmitted Biologics License Application for narsoplimab in TA-TMA, with a target action date set for September 25. Omeros Corp (NASDAQ:OMER) is well-prepared for the potential launch of narsoplimab, having identified key transplant centers and engaged with payers to ensure patient access. The company is advancing its pipeline with ongoing clinical trials for zaltenibart in PNH and OMS527 for cocaine use disorder, supported by a grant from the National Institute on Drug Abuse. Negative Points Omeros Corp (NASDAQ:OMER) reported a net loss of $33.5 million for the first quarter of 2025, an increase from the previous quarter. The company has suspended its Expanded Access Program for narsoplimab, affecting patients who lack approved treatment options for TA-TMA. There is a temporary pause on the Phase 3 program for zaltenibart in PNH due to capital considerations, potentially delaying its development timeline. OMIDRIA royalties decreased significantly in the first quarter of 2025 compared to the previous quarter, impacting revenue. Interest expense increased in the first quarter, driven by changes in the OMIDRIA royalty obligation and new convertible notes. Q & A Highlights Q: Can you provide details on the launch plans for narsoplimab and its impact on patient access? A: Greg Demopulos, Chairman & CEO, stated that the company is well-prepared for the launch, expecting it to be successful. Nadia Dac, Chief Commercial Officer, elaborated that the team is focused on the top 40 transplant centers responsible for 60% of the allogeneic transplant volume. They have identified key decision-makers and are engaging with payers, emphasizing narsoplimab's unique value as the only approved treatment for TA-TMA. Q: Can you provide more information about the patients affected by TA-TMA and the associated healthcare costs? A: Greg Demopulos explained that TA-TMA is an unpredictable complication of stem cell transplants, often resulting in rapid deterioration and high mortality. Nadia Dac added that untreated patients incur significant costs, such as ICU stays and organ failure treatments. Narsoplimab aims to reduce these costs by offering an effective outpatient treatment option. Q: How are you managing the financial aspects of the company, particularly regarding debt and capital raising? A: Greg Demopulos highlighted the recent exchange agreement that reduced the 2026 convertible notes' principal, lowering near-term repayment obligations by over $100 million. The company is also exploring partnerships for non-dilutive funding and has an active at-the-market facility to raise up to $150 million. Q: What are the strategic priorities for Omeros beyond narsoplimab? A: Greg Demopulos mentioned that the company is prioritizing the development of zaltenibart for paroxysmal nocturnal hemoglobinuria (PNH) and continuing its PDE7 inhibitor program for cocaine use disorder, funded by a NIDA grant. They are also advancing their oncology platform, Oncotox, targeting acute myeloid leukemia. Q: What is the current status of the narsoplimab BLA resubmission and its potential market impact? A: Greg Demopulos confirmed that the FDA has accepted the resubmitted BLA for narsoplimab in TA-TMA, with a target action date of September 25. The company anticipates narsoplimab to be the first approved therapy for TA-TMA, addressing a nearly $1 billion annual market opportunity. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
16 minutes ago
- Yahoo
Beeline Holdings Inc (BLNE) Q2 2025 Earnings Call Highlights: Strategic Divestment and Revenue ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Beeline Holdings Inc (NASDAQ:BLNE) successfully divested its spirits assets, allowing a full focus on its core digital mortgage lending business. The company reported a 27% increase in revenue and a 40% decrease in expenses in Q2 2025 compared to Q1 2025. Beeline Holdings Inc (NASDAQ:BLNE) introduced a new equity product that is not tied to interest rates, providing a competitive advantage. The AI sales agent, Bob, significantly improved lead conversion and mortgage application rates, contributing approximately $150,000 in revenue. The company reduced its debt by $6.2 million in 2025, aiming to be debt-free by November 1, 2025, and cash flow positive by January 2026. Negative Points The market remains challenging due to higher interest rates affecting refinance and purchase transactions. The company reported a net loss from continuing operations of $4 million for Q2 2025. There were $500,000 in one-time non-recurring expenses in Q2, impacting financial results. The broader launch of the new equity product has been delayed to ensure proper execution and customer satisfaction. Despite improvements, the company still faces significant scaling challenges and uncertainties in its new product offerings. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with BLNE. Q: Can you provide more details about the home equity cash-out product and the timing of its broader launch? A: (Nick Lauza, CEO) We initially planned to launch in late August or early September but decided to delay to ensure we get it right. The opportunity is massive, with untapped equity in the US market. The Genius Act provides regulatory clarity, and we want to ensure the product is perfect before scaling. We will conduct a select number of transactions over the next 30 to 45 days to gather feedback and ensure consumer interests are prioritized. Q: What are the assumptions behind your profitability projections for late this year or early next year? A: (Nick Lauza, CEO) We are focusing on achieving profitability quickly by cutting $225,000 in monthly recurring expenses, which will be fully realized by September. Our locks are up, and we've reduced our marketing budget by $40,000 monthly while maintaining strong performance. We also had $500,000 in one-time expenses in Q2, which won't recur. We aim to be debt-free by November 1 and cash flow positive by January 2026. Q: Can you explain the economics of the fractional products and the expected volume at scale? A: (Nick Lauza, CEO) Our margins will be higher than our mortgage products, with less work involved since we're underwriting the property, not the consumer. We expect about 33% more revenue per file. Marketing expenses will be minimal as our partner will drive the business. We've identified about 1,000 potential customers who would qualify for this product. Q: What will drive significant growth in 2026, even without rate cuts? A: (Nick Lauza, CEO) We expect strong demand for Beeline Equity, as it provides liquidity based on home equity rather than individual qualifications. This product is ideal for those who can't qualify for cash-out refis or HELOCs. Additionally, our mortgage business is improving, and we have a strong title business team. We anticipate the equity product to be our largest revenue generator in 2026, followed by the mortgage and title businesses. Q: Do you have a sensitivity analysis for how rate cuts could impact growth? A: (Nick Lauza, CEO) While we don't have specific figures, a 25 basis point cut would significantly impact our business as a centralized digital lender. Digital models perform better in low-rate environments, and a 1-point cut would lead to rapid growth. (Chris Moe, CFO) Additionally, the longer rates remain high, the more significant the impact of a cut due to pent-up demand. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Dare Bioscience Inc (NASDAQ:DARE) is on track to launch its sildenafil cream, Dare to Play, through a 503b outsourcing facility in Q4 2025, marking a significant milestone in women's sexual health. The company is advancing a differentiated clinical pipeline with grant-funded programs targeting unmet needs in contraception, HPV, and preterm birth. Dare Bioscience Inc (NASDAQ:DARE) received positive feedback from its direct-to-patient awareness campaign, highlighting significant interest in its products. The Oviprine Phase 3 trial continues as planned with no new safety concerns, supporting its potential as a hormone-free contraceptive option. The company strengthened its financial position with $17.6 million in net proceeds from stock sales and a $6 million grant payment, enhancing its ability to execute its strategy. Negative Points Dare Bioscience Inc (NASDAQ:DARE) ended the quarter with a working capital deficit of approximately $12.6 million. The company experienced a 71% decrease in R&D expenses compared to Q2 2024, primarily due to reductions in manufacturing and development costs. There were technical difficulties during the earnings call, preventing a Q&A session, which may have limited investor engagement. The company's dual path strategy involves risks associated with FDA approval processes and market acceptance of its products. Despite the progress, the company operates in a highly competitive market with significant challenges in bringing new women's health solutions to market. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with DARE. Q: What is the status of the Dare to Play Sildenafil Cream launch? A: Sabrina Martucci Johnson, President and CEO, stated that Dare Bioscience remains on track to support the commercial availability of Dare to Play Sildenafil Cream through a 503b outsourcing facility in the fourth quarter of 2025. This launch is a significant milestone for the company and the field of women's sexual health. Q: Can you provide an update on the Ovaprine Phase 3 trial? A: Sabrina Martucci Johnson explained that the Independent Data and Safety Monitoring Board reviewed interim data from the Phase 3 study and recommended that the trial continue as planned. The interim pregnancy rate was consistent with expectations, supporting Ovaprine's potential as a non-hormonal contraceptive option. Q: What is the dual commercialization pathway for DARE HRT1? A: Sabrina Martucci Johnson highlighted that DARE HRT1, an intravaginal ring for hormone therapy, is pursuing both FDA approval and a 503b compounding opportunity. This approach aims to accelerate patient access while generating necessary data for FDA approval. Q: How is Dare Bioscience expanding into consumer health products? A: Sabrina Martucci Johnson announced plans to launch two non-prescription vaginal probiotics to support vaginal microbiome health. These products will complement the prescription offerings and diversify the company's commercial platform. Q: What are the financial highlights for the second quarter of 2025? A: Marty Herringlayton, Chief Accounting Officer, reported that Dare Bioscience ended the quarter with approximately $5 million in cash and a working capital deficit of $12.6 million. Post-quarter, the company received $17.6 million from stock sales and a $6 million grant, strengthening its balance sheet. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
